Breast cancer in transgender female‐to‐male individuals: A case report of androgen receptor‐positive breast cancer

2019 ◽  
Vol 26 (5) ◽  
pp. 1007-1012 ◽  
Author(s):  
Adam Fundytus ◽  
Nathalie Saad ◽  
Natalie Logie ◽  
Gloria Roldan Urgoiti
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Androgen Receptor ◽  
Positive Breast Cancer

Complete Response of Metastatic Androgen Receptor–Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature

2016 ◽  
Vol 34 (4) ◽  
pp. e21-e24 ◽  
Author(s):  
Claudia Arce-Salinas ◽  
Maria Carmen Riesco-Martinez ◽  
Wedad Hanna ◽  
Philippe Bedard ◽  
Ellen Warner
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Androgen Receptor ◽  
Complete Response ◽  
Review Of The Literature ◽  
Positive Breast Cancer

The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer

2021 ◽  
Vol 27 (2) ◽  
pp. 310-320 ◽  
Author(s):  
Theresa E. Hickey ◽  
Luke A. Selth ◽  
Kee Ming Chia ◽  
Geraldine Laven-Law ◽  
Heloisa H. Milioli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Androgen Receptor ◽  
Tumor Suppressor ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

Repeated courses of radiation treatment in an HER2‐positive breast cancer patient with diffuse brain metastases: A case report

2020 ◽  
Vol 26 (7) ◽  
pp. 1370-1371
Author(s):  
Sonia Silipigni ◽  
Edy Ippolito ◽  
Paolo Matteucci ◽  
Bianca Santo ◽  
Emma Gangemi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Brain Metastases ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Radiation Treatment ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Diffuse Brain ◽  
Positive Breast Cancer

scholarly journals Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival

2019 ◽  
Vol 20 (11) ◽  
pp. 2655 ◽  
Author(s):  
Maiko Okano ◽  
Masanori Oshi ◽  
Ali Linsk Butash ◽  
Mariko Asaoka ◽  
Eriko Katsuta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
T Cells ◽  
Estrogen Receptor ◽  
Androgen Receptor ◽  
Tumor Infiltrating Lymphocytes ◽  
Cytolytic Activity ◽  
Er Positive ◽  
Infiltrating Lymphocytes ◽  
Response To Neoadjuvant Chemotherapy ◽  
Positive Breast Cancer

Estrogen receptor (ER) positive breast cancer (BC), the most abundant BC subtype, is notorious for poor response to neoadjuvant chemotherapy (NAC). The androgen receptor (AR) was reported to support estradiol-mediated ER activity in an in vitro system. Recently, ER-positive BC with fewer tumor infiltrating lymphocytes (TILs) was shown to have a better prognosis, opposite to the trend seen with ER-negative BC. We hypothesized that ER-positive BC with high expression of AR will have fewer TILs and an inferior response to NAC, but with a better prognosis. In both TCGA and METABRIC cohorts, AR expression was significantly higher in ER-positive BCs compared to ER-negatives (p < 0.001, p < 0.001, respectively) and it correlated with ER expression (R = 0.630, R = 0.509, respectively). In ER-positive tumors, AR high tumors enriched UV response down (NES = 2.01, p < 0.001), and AR low tumors enriched DNA repair (NES = −2.02, p < 0.001). AR high tumors were significantly associated with procancer regulatory T-cells, and AR low tumors were associated with anticancer immune cells, such as CD4, CD8, and Gamma-Delta T-cells and memory B-cells in ER-positive BC (p < 0.01). Further, cytolytic activity was significantly lower in AR high BC in both cohorts. Finally, AR high tumors had a significantly lower rate of attaining pathological complete response to NAC (GSE22358), but better survival. In conclusion, our results demonstrated that high AR has fewer tumor infiltrating lymphocytes as well as cytolytic activity and an inferior response to NAC, but better survival in ER-positive BC.

scholarly journals Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer

2019 ◽  
Vol 176 (1) ◽  
pp. 63-73 ◽  
Author(s):  
Sasagu Kurozumi ◽  
Chitra Joseph ◽  
Sara Raafat ◽  
Sultan Sonbul ◽  
Yousif Kariri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Prognostic Marker ◽  
Positive Breast Cancer

scholarly journals Androgen receptor signaling pathways as a target for breast cancer treatment

2016 ◽  
Vol 23 (10) ◽  
pp. R485-R498 ◽  
Author(s):  
Elisabetta Pietri ◽  
Vincenza Conteduca ◽  
Daniele Andreis ◽  
Ilaria Massa ◽  
Elisabetta Melegari ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Signaling Pathways ◽  
Triple Negative ◽  
Pubertal Development ◽  
Her2 Positive ◽  
Age Related ◽  
Clinical Scenarios ◽  
Er Positive ◽  
Positive Breast Cancer

The androgen receptor (AR) is a ligand-dependent transcription factor, and its effects on breast range from physiological pubertal development and age-related modifications to cancer onset and proliferation. The prevalence of AR in early breast cancer is around 60%, and AR is more frequently expressed in ER-positive than in ER-negative tumors. We offer an overview of AR signaling pathways in different breast cancer subtypes, providing evidence that its oncogenic role is likely to be different in distinct biological and clinical scenarios. In particular, in ER-positive breast cancer, AR signaling often antagonizes the growth stimulatory effect of ER signaling; in triple-negative breast cancer (TNBC), AR seems to drive tumor progression (at least in luminal AR subtype of TNBC with a gene expression profile mimicking luminal subtypes despite being negative to ER and enriched in AR expression); in HER2-positive breast cancer, in the absence of ER expression, AR signaling has a proliferative role. These data represent the rationale for AR-targeting treatment as a potentially new target therapy in breast cancer subset using androgen agonists in some AR-positive/ER-positive tumors, AR antagonists in triple-negative/AR-positive tumors and in combination with anti-HER2 agents or with other signaling pathways inhibitors (including PI3K/MYC/ERK) in HER2-positive/AR-positive tumors. Only the ongoing and future prospective clinical trials will allow us to establish which agents are the best option in every specific condition, keeping in mind that there is evidence of opposite androgens and AR agonist/antagonist drug effects on cell proliferation particularly in AR-positive/ER-positive tumors.

Sign in / Sign up

Export Citation Format

Share Document